TruScreen Completes Successful Capital Raising

Company Announcement 5 October 2018

TRUSCREEN COMPLETES SUCCESSFUL CAPITAL RAISING
Cervical cancer technology company, TruScreen Limited (TRU: NZAX) advises that it has successfully
completed its Share Purchase Plan (SPP) offer.
Chairman of TruScreen, Mr Tony Ho, said: “TruScreen has several immediate commercial
opportunities and the capital raised will enable us to maximise those opportunities. We are very
pleased with the support we have received from our shareholders, reflecting their confidence in our
strategy.”
TruScreen will issue 7,411,964 ordinary shares at NZD 21 cents each, totalling $1,556,500 in new
capital.
The SPP was the second stage of TruScreen’s equity capital raising programme and followed the
successful $1,500,000 placement to institutional and professional investors which was completed on
31 August 2018.
Funds will be used to:
• Build on and expand commercial growth in China, Africa, India and Latin America;
• Fund clinical and familiarisation trials as required for further product enhancement and
acceptance in government programs;
• Expand manufacturing and supply capabilities;
• Provide additional working capital; and
• Continued product development.
The SPP closed on 3 October 2018 and shares will be allotted on 9 October 2018.

ENDS
For more information visit www.truscreen.com or contact
Martin Dillon, TruScreen Chief Executive Officer,
email: martindillon@truscreen.com.

About TruScreen:
TruScreen’s real time cervical cancer
technology utilises a digital wand which is
placed on the surface of the cervix to measure
electrical and optical signals from the
surrounding tissue. A sophisticated proprietary
algorithm framework distinguishes between
normal and abnormal (cancerous and
precancerous) tissue to identify precancerous
change, or cervical intraepithelial neoplasia
(CIN). A Single Use Sensor (SUS) is used for
each patient to protect against cross-infection.
For further news update vist Truscreen Limited’s website at www.truscreen.com